270 related articles for article (PubMed ID: 37674501)
1. The 2023 Impact of Inflammatory Bowel Disease in Canada: Treatment Landscape.
Murthy SK; Weizman AV; Kuenzig ME; Windsor JW; Kaplan GG; Benchimol EI; Bernstein CN; Bitton A; Coward S; Jones JL; Lee K; Peña-Sánchez JN; Rohatinsky N; Ghandeharian S; Sabrie N; Gupta S; Brar G; Khan R; Im JHB; Davis T; Weinstein J; St-Pierre J; Chis R; Meka S; Cheah E; Goddard Q; Gorospe J; Kerr J; Beaudion KD; Patel A; Russo S; Blyth J; Blyth S; Charron-Bishop D; Targownik LE
J Can Assoc Gastroenterol; 2023 Sep; 6(Suppl 2):S97-S110. PubMed ID: 37674501
[TBL] [Abstract][Full Text] [Related]
2. The Impact of Inflammatory Bowel Disease in Canada 2018: Direct Costs and Health Services Utilization.
Kuenzig ME; Benchimol EI; Lee L; Targownik LE; Singh H; Kaplan GG; Bernstein CN; Bitton A; Nguyen GC; Lee K; Cooke-Lauder J; Murthy SK
J Can Assoc Gastroenterol; 2019 Feb; 2(Suppl 1):S17-S33. PubMed ID: 31294382
[TBL] [Abstract][Full Text] [Related]
3. The Impact of Inflammatory Bowel Disease in Canada 2018: Children and Adolescents with IBD.
Carroll MW; Kuenzig ME; Mack DR; Otley AR; Griffiths AM; Kaplan GG; Bernstein CN; Bitton A; Murthy SK; Nguyen GC; Lee K; Cooke-Lauder J; Benchimol EI
J Can Assoc Gastroenterol; 2019 Feb; 2(Suppl 1):S49-S67. PubMed ID: 31294385
[TBL] [Abstract][Full Text] [Related]
4. The Impact of Inflammatory Bowel Disease in Canada 2018: IBD in Seniors.
Nguyen GC; Targownik LE; Singh H; Benchimol EI; Bitton A; Murthy SK; Bernstein CN; Lee K; Cooke-Lauder J; Kaplan GG
J Can Assoc Gastroenterol; 2019 Feb; 2(Suppl 1):S68-S72. PubMed ID: 31294386
[TBL] [Abstract][Full Text] [Related]
5. The Impact of Inflammatory Bowel Disease in Canada 2018: Indirect Costs of IBD Care.
Kuenzig ME; Lee L; El-Matary W; Weizman AV; Benchimol EI; Kaplan GG; Nguyen GC; Bernstein CN; Bitton A; Lee K; Cooke-Lauder J; Murthy SK
J Can Assoc Gastroenterol; 2019 Feb; 2(Suppl 1):S34-S41. PubMed ID: 31294383
[TBL] [Abstract][Full Text] [Related]
6. Biologic targeting in the treatment of inflammatory bowel diseases.
Bosani M; Ardizzone S; Porro GB
Biologics; 2009; 3():77-97. PubMed ID: 19707398
[TBL] [Abstract][Full Text] [Related]
7. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
Magro F; Portela F
BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
[TBL] [Abstract][Full Text] [Related]
8. Biosimilars in inflammatory bowel disease.
Talathi S; Baig KRKK
J Dig Dis; 2020 Nov; 21(11):610-620. PubMed ID: 32920972
[TBL] [Abstract][Full Text] [Related]
9. Health-care costs of inflammatory bowel disease in a pan-European, community-based, inception cohort during 5 years of follow-up: a population-based study.
Burisch J; Vardi H; Schwartz D; Friger M; Kiudelis G; Kupčinskas J; Fumery M; Gower-Rousseau C; Lakatos L; Lakatos PL; D'Incà R; Sartini A; Valpiani D; Giannotta M; Arebi N; Duricova D; Bortlik M; Chetcuti Zammit S; Ellul P; Pedersen N; Kjeldsen J; Midjord JMM; Nielsen KR; Winther Andersen K; Andersen V; Katsanos KH; Christodoulou DK; Domislovic V; Krznaric Z; Sebastian S; Oksanen P; Collin P; Barros L; Magro F; Salupere R; Kievit HAL; Goldis A; Kaimakliotis IP; Dahlerup JF; Eriksson C; Halfvarson J; Fernandez A; Hernandez V; Turcan S; Belousova E; Langholz E; Munkholm P; Odes S;
Lancet Gastroenterol Hepatol; 2020 May; 5(5):454-464. PubMed ID: 32061322
[TBL] [Abstract][Full Text] [Related]
10. An update on biosimilar drugs for inflammatory bowel disease.
Schreiber S
Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():1-3. PubMed ID: 26395529
[TBL] [Abstract][Full Text] [Related]
11. Real-world data on the infliximab biosimilar CT-P13 (Remsima
Huguet JM; Cortés X; Bosca-Watts MM; Aguas M; Maroto N; Martí L; Amorós C; Paredes JM
World J Clin Cases; 2021 Dec; 9(36):11285-11299. PubMed ID: 35071559
[TBL] [Abstract][Full Text] [Related]
12. The 2023 Impact of Inflammatory Bowel Disease in Canada: Direct Health System and Medication Costs.
Kuenzig ME; Coward S; Targownik LE; Murthy SK; Benchimol EI; Windsor JW; Bernstein CN; Bitton A; Jones JL; Lee K; Peña-Sánchez JN; Rohatinsky N; Ghandeharian S; Im JHB; Jogendran R; Meka S; Weinstein J; Jones May T; Jogendran M; Tabatabavakili S; Hazan E; Hu M; Osei JA; Khan R; Wang G; Browne M; Davis T; Goddard Q; Gorospe J; Latos K; Mason K; Kerr J; Balche N; Sklar A; Kaplan GG
J Can Assoc Gastroenterol; 2023 Sep; 6(Suppl 2):S23-S34. PubMed ID: 37674493
[TBL] [Abstract][Full Text] [Related]
13. Biologic therapy for inflammatory bowel disease.
Ardizzone S; Bianchi Porro G
Drugs; 2005; 65(16):2253-86. PubMed ID: 16266194
[TBL] [Abstract][Full Text] [Related]
14. The 2023 Impact of Inflammatory Bowel Disease in Canada: Special Populations-IBD in Seniors.
Shaffer SR; Kuenzig ME; Windsor JW; Bitton A; Jones JL; Lee K; Murthy SK; Targownik LE; Peña-Sánchez JN; Rohatinsky N; Ghandeharian S; Tandon P; St-Pierre J; Natt N; Davis T; Weinstein J; Im JHB; Benchimol EI; Kaplan GG; Goddard Q; Gorospe J; Bergevin M; Silver K; Bowles D; Stewart M; Pearlstein M; Dawson EH; Bernstein CN
J Can Assoc Gastroenterol; 2023 Sep; 6(Suppl 2):S45-S54. PubMed ID: 37674503
[TBL] [Abstract][Full Text] [Related]
15. Inflammatory bowel disease surgery in the biologic era.
Ferrari L; Krane MK; Fichera A
World J Gastrointest Surg; 2016 May; 8(5):363-70. PubMed ID: 27231514
[TBL] [Abstract][Full Text] [Related]
16. Impact of biologic therapies and small molecules on the risk of major adverse cardiovascular events in patients with inflammatory bowel diseases: systematic review and meta-analysis of randomized controlled trials.
Shehab M; Alrashed F; Alkazemi A; Lakatos PL; Bessissow T
Expert Rev Gastroenterol Hepatol; 2023 May; 17(5):469-477. PubMed ID: 36961082
[TBL] [Abstract][Full Text] [Related]
17. Current, new and future biological agents on the horizon for the treatment of inflammatory bowel diseases.
Amiot A; Peyrin-Biroulet L
Therap Adv Gastroenterol; 2015 Mar; 8(2):66-82. PubMed ID: 25729432
[TBL] [Abstract][Full Text] [Related]
18. The Impact of Inflammatory Bowel Disease in Canada 2018: Extra-intestinal Diseases in IBD.
Bernstein CN; Benchimol EI; Bitton A; Murthy SK; Nguyen GC; Lee K; Cooke-Lauder J; Kaplan GG
J Can Assoc Gastroenterol; 2019 Feb; 2(Suppl 1):S73-S80. PubMed ID: 31294387
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of Dual Biologic Therapy in Patients With Inflammatory Bowel Disease: A Review of the Literature.
Gold SL; Steinlauf AF
Gastroenterol Hepatol (N Y); 2021 Sep; 17(9):406-414. PubMed ID: 34602905
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
